These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9548267)

  • 1. Hepatitis C associated with Guillain-Barré syndrome.
    Lacaille F; Zylberberg H; Hagège H; Roualdès B; Meyrignac C; Chousterman M; Girot R
    Liver; 1998 Feb; 18(1):49-51. PubMed ID: 9548267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose intravenous immune globulin in the management of severe Guillain-Barre syndrome.
    Baskin E; Turkay S; Icagasioglu D; Tanzer F; Cevit O
    Turk J Pediatr; 1996; 38(1):119-23. PubMed ID: 8819632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe Guillain-Barré syndrome associated with chronic active hepatitis C and mixed cryoglobulinemia: a case report.
    Chlilek A; Roger C; Muller L; Carles MJ; Stephan R; Laureillard D; Lavigne JP; Lefrant JY; Sotto A
    BMC Infect Dis; 2019 Jul; 19(1):636. PubMed ID: 31315560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome.
    Gürses N; Uysal S; Cetinkaya F; Işlek I; Kalayci AG
    Scand J Infect Dis; 1995; 27(3):241-3. PubMed ID: 8539548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Guillain-Barré syndrome associated with Campylobacter jejuni infection with failure to respond to plasmapheresis and immunoglobulin.
    Allen A; Antony SJ
    J Am Board Fam Pract; 1999; 12(3):249-52. PubMed ID: 10395423
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of Guillain-barre syndrome: immunoglobulins or plasmapheresis?].
    Martínez Yélamos A; Huerta Villanueva M; Olivé Plana M; Montero Homs J; Serra Catafau J; Martínez-Matos JA
    Neurologia; 1998 Apr; 13(4):166-9. PubMed ID: 9608755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guillain-Barré syndrome with autoimmune hemolytic anemia following acute viral hepatitis.
    Perseghin P; Balduini CL; Piccolo G; Bertolino G; Bellusci M; Scelsi R; Mauri C
    Ital J Neurol Sci; 1985 Dec; 6(4):447-50. PubMed ID: 4086264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasmapheresis vs intravenous immunoglobulin treatment in childhood Guillain-Barré syndrome.
    Vajsar J; Sloane A; Wood E; Murphy EG
    Arch Pediatr Adolesc Med; 1994 Nov; 148(11):1210-2. PubMed ID: 7921126
    [No Abstract]   [Full Text] [Related]  

  • 9. [Extrahepatic manifestations of chronic hepatitis C].
    Ignatova TM; Aprosina ZG; Serov VV; Mukhin NA; Krel' PE; Semenkova EN; Popova IV; Tanashchuk EL
    Ter Arkh; 1998; 70(11):9-16. PubMed ID: 9949448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Plasmapheresis and high-dose immunoglobulins in the treatment of acute demyelinating polyneuropathy].
    Marino A; Logi G; Roncucci P; Sodini ML; Fornaini F
    Minerva Anestesiol; 1993 Jun; 59(6):307-11. PubMed ID: 8414090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guillain-Barré syndrome: rare extra-intestinal manifestation of hepatitis B.
    Sonavane AD; Saigal S; Kathuria A; Choudhary NS; Saraf N
    Clin J Gastroenterol; 2018 Aug; 11(4):312-314. PubMed ID: 29542024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of Guillain-Barré syndrome with focal segmental glomerulosclerosis.
    Careless D; Rigby R; Axelsen R; Boyle R
    Am J Nephrol; 1993; 13(2):160-3. PubMed ID: 8342584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guillain-Barré syndrome.
    Winer J
    Br J Hosp Med; 1994 Mar 16-Apr 5; 51(6):313. PubMed ID: 8032572
    [No Abstract]   [Full Text] [Related]  

  • 14. Plasmapheresis treatment in Guillain-Barré syndrome: potential benefit over intravenous immunoglobulin.
    Buzzigoli SB; Genovesi M; Lambelet P; Logi C; Raffaelli S; Cattano D
    Anaesth Intensive Care; 2010 Mar; 38(2):387-9. PubMed ID: 20369779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic hepatitis B exacerbated by Guillain-Barré syndrome: a report of two cases.
    Han HF; Wu JC; Huo TI; Kao KP; Huang YH; Chang FY; Lee SD
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Sep; 62(9):652-6. PubMed ID: 10502859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
    Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group.
    Visser LH; Van der Meché FG; Van Doorn PA; Meulstee J; Jacobs BC; Oomes PG; Kleyweg RP; Meulstee J
    Brain; 1995 Aug; 118 ( Pt 4)():841-7. PubMed ID: 7655882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropathies in HIV infection.
    Dalakas MC; Cupler EJ
    Baillieres Clin Neurol; 1996 Mar; 5(1):199-218. PubMed ID: 8732208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function.
    Créange A; Bélec L; Clair B; Degos JD; Raphaël JC; Gherardi RK
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):162-5. PubMed ID: 9489524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulin in two children with Guillain-Barré syndrome.
    Notarangelo LD; Duse M; Tiberti S; Guarneri B; Brunori A; Negrini A; Ugazio AG
    Eur J Pediatr; 1993 Apr; 152(4):372-4. PubMed ID: 8482293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.